Researchers at the National Institutes of Health have discovered a genetic mutation that appears to increase production of red blood cells in tumors. The discovery, based on analysis of tissue from rare endocrine tumors, may help clarify how some tumors generate a new blood supply to sustain their growth, the researchers explained.
PITTSBURGH, Sept. 17, 2012 /PRNewswire/ -- Carnegie Mellon University's Adam W. Feinberg was awarded a five-year, $2.25 million National Institutes of Health (NIH) Director's New Innovator Award to continue developing new biomaterials and cardiac tissue engineering strategies to help repair the human heart following injury and disease.
THE WOODLANDS, Texas--(BUSINESS WIRE)--Sep 17, 2012 - Opexa Therapeutics, Inc., a company developing Tcelna, a novel T-cell therapy for multiple sclerosis (MS), today announced that Neil Warma, President and Chief Executive Officer, will attend the upcoming UBS Global Life Sciences Conference.
PARSIPPANY, N.J. and MUMBAI, India, Sept. 17, 2012 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, which is used in treatment of peptic ulcers.
New York, September 17, 2012–– Sudler & Hennessey, one of the leading global healthcare communication agencies, is pleased to announce that Rob Rogers, co-CEO, the Americas, has been selected to receive the 2012 CLIO Healthcare Lifetime Achievement Award, to be presented at the 4th annual CLIO Healthcare Awards event on November 13, 2012, in New York City.
September 17, 2012, Billerica, MA — EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, and iPS Academia Japan, Inc. (Kyoto, Japan) today announced a global licensing agreement for AJ’s induced pluripotent stem (iPS) cell patent portfolio
Bloomington, Ind., September 17, 2012—Victor Vinci, Ph.D., has joined Cook Pharmica’s leadership team as vice president and chief scientific officer. Vinci will be responsible for guiding the scientific direction of Cook Pharmica, applying his more than 20 years of broad technical, managerial and leadership experience.
(Lincoln, NE; Sep 17, 2012) – Celerion, the premier provider of innovative early stage drug development solutions, is pleased to announce that it has been awarded full accreditation by the Association for the Accreditation Human Research Protection Programs (AAHRPP). Celerion’s clinical facilities in the USA; Lincoln NE; Neptune NJ; and Phoenix AZ, have achieved this significant milestone.
17 September 2012: Bionomics Limited (ASX:BNO, ADR:BMICY) has acquired San Diego-based private biotechnology company Eclipse Therapeutics Inc (Eclipse) in a scrip-based US$10 million deal. With consideration of approximately 23.9 million shares at 41.76 cents per share, Eclipse shareholders, that include NASDAQ-listed Biogen Idec, will own approximately 6.5% of Bionomics’ issued capital.
Washington, DC (September 14, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that two companies – Ipsen Biopharmaceuticals and Onyx Pharmaceuticals – have joined the association as new research associate members. PhRMA’s Board of Directors recently approved the membership expansion.
ATLANTA--(BUSINESS WIRE)--Sep 17, 2012 - THE SAGE GROUP LLC announced today that Mary L. Yost was a panelist in the recently released Medscape Continuing Medical Education (CME) Program Titled “The Price of PAD: The Clinical and Economic Consequences of Amputation”.
BETHESDA, Md.--(BUSINESS WIRE)--Sep 17, 2012 - Wondering how many top life sciences CEOs got where they are today? The 2012 Mid-Atlantic Bio Conference, taking place September 27-28 at the Bethesda Marriott, will give attendees the inside track on how area biotech CEOs found their way to the top during a panel on building value and planning exits.
MINNETONKA, Minn., Sept. 17, 2012 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that the latest version of iMedNet EDC is now available.
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Sep 17, 2012 - Diffusion Pharmaceuticals LLC, a biotechnology company developing innovative cancer treatments for major unmet medical needs, today announced that it has closed a $5 million private financing.
NEW YORK, Sept. 17, 2012 /PRNewswire/ -- Citeline, an Informa business, reviewed clinical trial data presented at the European Respiratory Society (ERS) conference, held September 1-5, 2012 in Vienna, Austria, noting that classical fixed-dose combination (FDC) treatments remain a focus of industry sponsors, but that novel targeted asthma drugs may also be on the horizon for persistent asthma patients.
NEW YORK--(BUSINESS WIRE)--Sep 17, 2012 - Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.
LA JOLLA, Calif., Sept. 17, 2012 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic-driven solutions to solve a range of global challenges, today announced they have purchased from Febit Holding GmbH the worldwide rights to three families of patents and patent applications related to key synthetic genomic technologies.
LOS ANGELES--(BUSINESS WIRE)--Sep 17, 2012 - Targeted Medical Pharma, Inc., a specialty pharmaceutical company that develops and distributes prescription medical foods to physicians, pharmacies and skilled nursing facilities, today unveiled preliminary data indicating that its new amino acid oral formulation stimulated red blood cell and platelet development during an investigational study.
WATERTOWN, Mass.--(BUSINESS WIRE)--Sep 17, 2012 - pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2012 will be released after the market close on Monday, September 24, 2012, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
WUERZBURG, Germany, September 17, 2012 /PRNewswire/ -- vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
MALVERN, Pa.--(BUSINESS WIRE)--Sep 17, 2012 - Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled “A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance” (Chauhan et al, Cancer Cell).
BERLIN, Sept. 17, 2012 /PRNewswire/ -- Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma.
HELSINKI, Finland and SAN FRANCISCO, September 17, 2012 /PRNewswire/ --MediSapiens launches first-in-kind fully integrated and unified cloud computing application that harnesses the power of Big Data and enables knowledge-based drug discovery and repositioning for personalized genomics.
PALO ALTO, Calif., Sept. 17, 2012 /PRNewswire/ -- Varian Medical Systems, a world leader in radiotherapy and X-Ray imaging technology, is announcing the publication of its 2012 Corporate Social Responsibility (CSR) report, detailing the company's policies and achievements in extending care, protecting resources and helping to save lives.
CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant.
NOKOMIS, Fla.--(BUSINESS WIRE)--Sep 17, 2012 - Rainbow Biosciences, the biotechnology subsidiary of Rainbow Coral Corp., announced today that it will expand its focus on technology capable of culturing 3D cell clusters to include adult stem cells, as well.
BETHESDA, Md.--(BUSINESS WIRE)--Sep 17, 2012 - Sucampo Pharmaceuticals, Inc. today announced that it plans to host an Analyst Meeting, open to members of the professional investment community, on September 28, 2012, from 8:00 to 11:00 am in New York City.
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the UBS Global Life Sciences Conference in New York City on Thursday, September 20th at 4:30 p.m. ET.
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Sep 17, 2012 - AB SCIEX, a global leader in life science analytical technologies, today announced a global initiative focused on biologics.
NEW HAVEN, Conn.--(BUSINESS WIRE)--Sep 17, 2012 - Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
MEMPHIS, Tenn.--(BUSINESS WIRE)--Sep 17, 2012 - GTx, Inc. announced today that it is sponsoring a symposium on Muscle Wasting in Non-Small Cell Lung Cancer Patients at 12:00 pm eastern daylight time on September 22, 2012, at the Hilton Back Bay Hotel in Boston Massachusetts.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 17, 2012 - ARIAD Pharmaceuticals, Inc. today announced that the initial data from its Phase 1/2 trial of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), will be presented at the ESMO 2012 Congress of the European Society for Medical Oncology (ESMO) being held in Vienna, Austria, September 28 to October 2, 2012.